BACKGROUND AND PURPOSE:The optimal sequencing of chemotherapy and proton therapy (PT) for locally advanced pancreatic cancer (LAPC) remains to be elucidated. This study aimed to evaluate the clinical outcomes of PT in relation to prior chemotherapy and identify the most effective timing for PT within multidisciplinary treatment. MATERIALS AND METHODS:This retrospective study reviewed the medical records of 146 patients with LAPC who underwent PT between September 2014 and August 2022 at a single institution. Patients were categorized into three groups: upfront (PT as initial treatment), non-failure (PT after chemotherapy with disease control), and failure (PT after discontinuation of chemotherapy due to disease progression or toxicity). Overall survival (OS) and progression-free survival (PFS) were analyzed from both the initiation of first-line treatment and start of PT. RESULTS:The median OS for the entire cohort was 20.1 months from the start of initial treatment and 17.1 (95% CI: 13.3-19.0) months from PT initiation. The median OS from first-line treatment in the non-failure, failure, and upfront treatment groups was 30.7 (95% CI: 16.0-42.7), 21.2 (95% CI: 17.8-24.1), and 17.8 (95% CI: 13.9-22.0) months, respectively (P = .030). From PT initiation, the median OS was 26.3 (95% CI: 11.1-40.8), 11.9 (95% CI: 9.3-14.9), and 17.8 (95% CI: 13.9-22.0) months, respectively (P = .001). The non-failure group also exhibited the longest PFS (P = .003). Late grade ≥3 gastrointestinal ulceration was observed in 3.0% of patients, including one case of suspected treatment-related gastric perforation. CONCLUSION:Improved survival outcomes may be achieved when PT is administered for disease control following induction chemotherapy. These findings highlight the importance of treatment sequencing and patient selection in LAPC management.
Evaluation of calcified lesions by intravascular imaging has revealed that atherectomy devices have only limited impact. However, subsequent use of coronary intravascular lithotripsy (IVL) may increase treatment effectiveness without increasing risk of complications. This study was designed to evaluate the safety and effectiveness of IVL use after atherectomy in severely calcified coronary lesions as pre-treatment for drug-eluting stents (DES). The Dual-Prep registry is a multicenter, prospective registry of consecutive image-guided percutaneous coronary interventions (PCI). The primary effectiveness and safety endpoints were procedural success (residual stenosis < 50% by quantitative coronary angiography) without an in-hospital major adverse cardiac event (MACE) and 30-day freedom from MACE, respectively. Baseline vessel calcification score and final DES expansion were evaluated by optical coherence tomography (OCT). A total of 118 patients with 120 lesions were enrolled at 20 sites. The calcification score of lesions after atherectomy by core-lab assessment was 4.0 in all cases. Rotational atherectomy was applied prior to IVL in 83.9% cases with mean burr size of 1.57 ± 0.20 mm; IVL was subsequently successfully delivered in all cases (mean balloon diameter 3.02 ± 0.45 mm), followed by DES deployment (mean diameter 3.19 ± 0.51 mm, length of 36.3 ± 16.0 mm). The primary efficacy and safety endpoints were met in 98.3% and 98.3% of cases, respectively. A DES expansion index < 0.8 was seen in 42.2%, and an eccentricity index < 0.7 was not observed in any patient. In severely calcified lesions, image-guided atherectomy followed by IVL lesion preparation demonstrated high procedural success rates and satisfactory non-eccentric stent expansion. This approach may be considered for lesions where an ‘IVL-first’ strategy may not be feasible. jRCT1032230384 (Oct 7, 2023). Graphical abstract Dual-Prep registry : atherectomy + IVL before DES implantation strategy for calcified lesion (Calc score ≥ 3 after atherectomy)
Predictive models for determining coronavirus disease 2019 (COVID-19) severity have been established; however, the complexity of the interactions among factors limits the use of conventional statistical methods. This study aimed to establish a simple and accurate predictive model for COVID-19 severity using an explainable machine learning approach. A total of 3,301 patients ≥ 18 years diagnosed with COVID-19 between February 2020 and October 2022 were included. The discovery cohort comprised patients whose disease onset fell before October 1, 2020 (N = 1,023), and the validation cohort comprised the remaining patients (N = 2,278). Pointwise linear and logistic regression models were used to extract 41 features. Reinforcement learning was used to generate a simple model with high predictive accuracy. The primary evaluation was the area under the receiver operating characteristic curve (AUC). The predictive model achieved an AUC of ≥ 0.905 using four features: serum albumin levels, lactate dehydrogenase levels, age, and neutrophil count. The highest AUC value was 0.906 (sensitivity, 0.842; specificity, 0.811) in the discovery cohort and 0.861 (sensitivity, 0.804; specificity, 0.675) in the validation cohort. Simple and well-structured predictive models were established, which may aid in patient management and the selection of therapeutic interventions.